Allostery Investments’s BridgeBio Pharma BBIO Stock Holding History

Allostery Investments’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-4,000	Closed	-$173K	–	7
2025 Q2	$173K	Sell	4,000 -76,000	-95%	-$2.76M	2.2%	13
2025 Q1	$2.77M	Buy	+80,000	New	+$2.7M	3.99%	12

Other funds holding BBIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Allostery Investments's BBIO Position: Q3 2025 in Review

Allostery Investments sold out of BridgeBio Pharma (BBIO) in Q3 2025, closing a stake of 4,000 shares — an estimated $173K sold.

Allostery Investments first reported a position in BBIO in Q1 2025 and held it in 2 quarters. The position peaked at $2.77M in Q1 2025. 392 funds tracked by Wall St. Rank hold BBIO as of Q3 2025.

Allostery Investments reported no remaining BridgeBio Pharma position as of Q3 2025 after selling out during the quarter.
Allostery Investments sold 4,000 BridgeBio Pharma shares in Q3 2025, an estimated $173K.
Allostery Investments first reported a position in BridgeBio Pharma in Q1 2025 and held it in 2 quarters.
Allostery Investments's BridgeBio Pharma position peaked at $2.77M in Q1 2025.
392 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2025.

Based on Allostery Investments's 13F filing for Q3 2025.